Cargando…

Interactions of the protease inhibitor, ritonavir, with common anesthesia drugs

The protease inhibitor, ritonavir, is a strong inhibitor of CYP 3A. The drug is used for management of the human immunovirus and is currently part of an oral antiviral drug combination (nirmatrelvir–ritonavir) for the early treatment of SARS‐2 COVID‐19‐positive patients aged 12 years and over who ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svedmyr, Anders, Hack, Henrik, Anderson, Brian J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Educational Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543968/ https://www.ncbi.nlm.nih.gov/pubmed/35842922 http://dx.doi.org/10.1111/pan.14529

Ejemplares similares

Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir
por: Gonzalez-García, Ruben, et al.
Publicado: (2023)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies
por: Sato, Akinori
Publicado: (2015)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
por: Cingolani, A, et al.
Publicado: (2010)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018)

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID‐19, in Subjects With Renal Impairment
por: Toussi, Sima S., et al.
Publicado: (2022)

Performance Accuracy of Hand-on-needle versus Hand-on-syringe Technique for Ultrasound-guided Regional Anesthesia Simulation for Emergency Medicine Residents
por: Johnson, Brian, et al.
Publicado: (2014)

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR
por: Wyatt, Christina M., et al.
Publicado: (2020)

Reconfiguring the scope and practice of regional anesthesia in a pandemic: the COVID-19 perspective
por: Ashokka, Balakrishnan, et al.
Publicado: (2020)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications
por: Agarwal, Shubham, et al.
Publicado: (2020)

Educational Review: Error traps in anesthesia for pediatric liver transplantation
por: Ballard, Heather A., et al.
Publicado: (2022)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
por: Ucciferri, Claudio, et al.
Publicado: (2016)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Midlatency auditory evoked potentials during anesthesia in children: A narrative review
por: Cheung, Yuen M., et al.
Publicado: (2021)

Potential pharmacokinetic interactions with concurrent use of herbal medicines and a ritonavir-boosted COVID-19 protease inhibitor in low and middle-income countries
por: Smith, Dallas J., et al.
Publicado: (2023)

Relevance of the drug–drug interactions between lidocaine and the pharmacokinetic enhancers ritonavir and cobicistat
por: Dekkers, Bart G.J., et al.
Publicado: (2019)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Impact of surgery and anesthesia during early brain development: A perfect storm
por: Keunen, Kristin, et al.
Publicado: (2022)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
por: Deutsch, Liat, et al.
Publicado: (2020)

Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
por: Teixeira, Rosângela, et al.
Publicado: (2013)

Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir()
por: Brandariz-Nuñez, David, et al.
Publicado: (2020)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapy
por: Igho-Osagie, Ebuwa, et al.
Publicado: (2023)

Perioperative anesthesia care for the pediatric patient undergoing a kidney transplantation: An educational review
por: Voet, Marieke, et al.
Publicado: (2021)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

An Interactive Module to Teach Common Biostatistical Tests to Learners in the Health Professions
por: Hayes, Patricia M, et al.
Publicado: (2023)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware
por: Ratain, Mark J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7g7fbsuev82tnfc9p40pqhhkj